Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Medtronic
Express Scripts
Johnson and Johnson
Dow

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

EMADINE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Emadine patents expire, and what generic alternatives are available?

Emadine is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EMADINE is emedastine difumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the emedastine difumarate profile page.

Drug patent expirations by year for EMADINE
Drug Prices for EMADINE

See drug prices for EMADINE

Recent Litigation for EMADINE

Identify potential future generic entrants

District Court Litigation
Case NameDate
AstraZeneca Pharmaceuticals LP v. Apotex Inc.2007-12-11
MedPointe Healthcare Inc. v. Apotex Inc.2007-04-17

See all EMADINE litigation

Pharmacology for EMADINE
Synonyms for EMADINE
1-(2-Ethoxy-ethyl)-2-(4-methyl-[1,4]diazepan-1-yl)-1H-benzoimidazole
1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole
1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-1,3-benzodiazole
1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzimidazole
1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1h-benzo[d]imidazole
1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole
1-(2-ethoxyethyl)-2-(4-methylhexahydro-1h-1,4-diazepine-1-yl)-1h-benzimidazole
1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole
1-(2-ethoxyethyl)-2-[(hexahydro-4-methyl-1h-1,4-diazepin)-1-yl]-1h-benzimidazole
1-[2-(ethoxy)ethyl]-2-(4-methyl-1-homopiperazinyl)benzimidazole
1-Methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazo)-2-yl)(1,4)diazepane
1-methyl-4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)[1,4]diazepane
1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-
233E612
87233-61-2
87233-62-3 (difumarate)
9J1H7Y9OJV
AC1L1FFW
AN-35537
BCP20085
BDBM50019624
BRD-K15010214-313-01-6
C-23705
C07785
C17H26N4O
CC-27452
CHEBI:4779
CHEMBL594
D07890
DB01084
DTXSID7048243
Emadine (TN)
Emedastina
Emedastina [INN-Spanish]
emedastine
Emedastine (INN)
Emedastine [INN:BAN]
Emedastine [INN]
Emedastinum
Emedastinum [INN-Latin]
EX-A1371
FT-0693271
GTPL7174
K557
KB 2413
KB-50524
KBUZBQVCBVDWKX-UHFFFAOYSA-N
KG 2413
L001093
LS-177979
MolPort-006-167-701
NCGC00181341-01
SCHEMBL29770
UNII-9J1H7Y9OJV
ZINC1530912

US Patents and Regulatory Information for EMADINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis EMADINE emedastine difumarate SOLUTION/DROPS;OPHTHALMIC 020706-001 Dec 29, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EMADINE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EMADINE emedastine difumarate SOLUTION/DROPS;OPHTHALMIC 020706-001 Dec 29, 1997   Start Trial   Start Trial
Novartis EMADINE emedastine difumarate SOLUTION/DROPS;OPHTHALMIC 020706-001 Dec 29, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
Dow
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.